Platform technologies are considered a valuable tool to improve efficiency and quality in drug product development. The basic idea is that a platform, in combination with a risk-based approach, is the most systematic method to leverage prior knowledge for a given new molecule. Learn more about the innovative technology platforms from our three presenters and how you can benefit from these. A delicious lunch will be provided during this interesting session.

The platform of Immunoprecise supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. Glycostem has taken a new approach to cellular immunotherapy manufacturing and will introduce the difference. And Single Cell Discoveries will present single-cell sequencing platforms as a service; you will learn what single-cell sequencing is and how it was developed.

ImmunoPrecise

Highly diverse functional therapeutic antibody lead panel selection by sourcing chicken and human B-cell repertoires. Therapeutic antibody campaigns heavily benefit from high diversity, not only on the sequence level, but also with respect to epitope coverage and functionality. This aspect should be taken into account at each step of a discovery program. The presented case study focuses on the generation of a diversified panel of antibodies directed against a transmembrane protein which is described to play a role in the development of cancer and neurodegenerative diseases via different mechanisms of actions. Leveraging two distinct, robust, species-agnostic antibody discovery platforms selected to circumvent immune tolerance, we were able to rapidly isolate a diverse panel of multi-species, target-specific antibodies from our in-house human scFv-repertoires and chicken B cell pools. Subsequent high-throughput characterizations facilitated the binning of antibodies based on the epitope landscape profile and functionality for follow-up in in vitro proof of concept studies to address the different therapeutic options, including ADC-based approaches and bispecific-oriented strategies.

Company description ImmunoPrecise
ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company endeavors to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes.

Single Cell Discoveries

Single-cell sequencing is a rapidly growing field that gains more and more interest from academia, biotech, and pharma. At Single Cell Discoveries, we offer multiple single-cell sequencing platforms as a service. Join our talk to find out what single-cell sequencing is, how it was developed, and which platforms we offer. We will discuss the biology of our single-cell platforms and how we work as a service provider.

Company description Single Cell Discoveries
Single Cell Discoveries is a single-cell sequencing service provider, founded in 2018 as a spin-off from the Hubrecht Institute. Located in Utrecht, we perform single-cell and spatial sequencing for academic institutes and companies from all over the world. We offer an end-to-end service to our clients, from project design to data analysis.

Glycostem

Glycostem has taken a new approach to cellular immunotherapy manufacturing and will introduce the difference. Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in the control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM).

Company description Glycostem
Over the last decade Glycomstem studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK cell production processes. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.
During our phase I safety study we verified our lead product oNKord® (naked NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second product: Chimeric Antigen Receptor (CAR)-engineered NK cells. This second-generation product has dedicated functionality, enhances tumor targeting and prolongs persistence.